The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
暂无分享，去创建一个
O. Mirallas | V. Arrazubi | P. Jiménez-Fonseca | J. Gallego | L. Visa | J. Cano | A. Carmona-Bayonas | A. Custodio | A. Fernández Montes | L. Gómez González | W. Mansoor | Marta Martín Richard | M. Mangas | N. Martínez Lago | Alfonso Martín Carnicero | M. Limón | C. Hernández Pérez | P. Pimentel | P. Cerda | P. Reguera | S. Raby | V. Foy | A. Calvo | M. Granja | R. Vidal Tocino | T. Saurí | Lola Macia-Rivas | Raquel Hernandez San Gil | D. Gutiérrez Abad | Francisco García Navalón | M. Gil Raga | Diego Cacho Lavín | Ismael Macías Declara | Vilma Pacheco Barcia | M. Ruiz Martín | J. Weaver